OncoMatch/Clinical Trials/NCT06311227
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Is NCT06311227 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Venetoclax for recurrent hairy cell leukemia.
Treatment: Venetoclax — This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hairy Cell Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: purine analog therapy
after purine analog therapy
Cannot have received: BRAF inhibitor
Exception: relapsed from or are ineligible for BRAF therapy
relapsed from or are ineligible for BRAF therapy
Cannot have received: BCL-2 inhibitor (venetoclax)
have not received prior venetoclax
Lab requirements
Kidney function
Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 45 mL/min/1.73m^2
Liver function
Total bilirubin ≤ 3 x institutional upper limit of normal (ULN) unless consistent with Gilbert's (ratio between total and direct bilirubin > 5); AST/ALT ≤ 3 × institutional ULN
Cardiac function
NYHA class 2B or better if cardiac disease or prior cardiotoxic agents
Total bilirubin ≤ 3 x institutional upper limit of normal (ULN) unless consistent with Gilbert's (ration between total and direct bilirubin > 5) Aspartate aminotransferase (AST).../alanine aminotransferase (ALT)... ≤ 3 × institutional ULN Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 45 mL/min/1.73m^2 ...should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Comprehensive Cancer Center · Duarte, California
- City of Hope at Irvine Lennar · Irvine, California
- UM Sylvester Comprehensive Cancer Center at Aventura · Aventura, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Gables · Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs · Coral Springs, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify